CrossrefInfokarte
Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study
International Journal of Urology · 2026-06 · 33 (6)
DOI: 10.1111/iju.70545 ↗Abstract
Kein Abstract verfügbar.
EUVIMED